Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Better Outcomes in High-Risk Multiple Myeloma

November 9th 2017

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.

FDA Approves Vemurafenib for Rare Blood Cancer

November 6th 2017

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.

R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma

November 3rd 2017

According to phase III results from the FOLL05 trial, the combination of rituximab plus cyclophosphamide, vincristine, and prednisone produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma.

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

FDA Approval Sought for Frontline Brentuximab Vedotin for Hodgkin Lymphoma

November 3rd 2017

A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma.

Dr. Perl on the Outlook of FLT3 Inhibitors for AML

November 3rd 2017

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

EFS at 24 Months May Predict Overall Survival in PTCL

November 2nd 2017

Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.

Guadecitabine Highly Active in AML

November 2nd 2017

More than half of elderly, treatment-naïve patients with AML assigned to treatment with guadecitabine had a composite complete response irrespective of dosage or schedule.

Expert Highlights CAR T-Cell Breakthroughs

November 1st 2017

David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

Dr. Awan Discusses Combinations With Ibrutinib in CLL

October 31st 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Dr. Frankfurt on the Future of AML Treatments

October 30th 2017

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Dr. Brammer on Updates in the Treatment Landscape for T-Cell Lymphoma

October 30th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

Novel Agents Show Impressive Activity in Hodgkin Lymphoma

October 28th 2017

Jane N. Winter, MD, discusses immunotherapy in the treatment of patients with Hodgkin lymphoma.

Emerging Treatments Show Promise in Myelofibrosis

October 27th 2017

Alice Mims, MD, provides updates on the field of myeloproliferative neoplasms, with a focus on myelofibrosis.

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

October 26th 2017

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma

October 26th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

EZH2 Inhibitor Tested as Epigenetic Option in NHL Types

October 26th 2017

Tazemetostat, a small molecule that targets epigenetic activity of the EZH2 gene, is being investigated as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma.

Dr. Mehta Discusses Combinations in Multiple Myeloma

October 26th 2017

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL

October 25th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

No Benefit With Prolonged Native E. Coli Asparaginase in Pediatric ALL, NHL

October 25th 2017

Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia or non-Hodgkin lymphoma not only failed to improve survival versus the standard regimen, but also resulted in an increase in infections and allergy.